NZ764110A - Compositions and methods for modulating pkk expression - Google Patents
Compositions and methods for modulating pkk expressionInfo
- Publication number
- NZ764110A NZ764110A NZ764110A NZ76411015A NZ764110A NZ 764110 A NZ764110 A NZ 764110A NZ 764110 A NZ764110 A NZ 764110A NZ 76411015 A NZ76411015 A NZ 76411015A NZ 764110 A NZ764110 A NZ 764110A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- compositions
- compounds
- modulating
- pkk
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Abstract
Disclosed herein are antisense oligonucleotide compounds and methods for decreasing prekallikrein (PKK) mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions. In an embodiment the compounds have a N-Acetylgalactosamine (GalNAc) conjugate group attached to them.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987478P | 2014-05-01 | 2014-05-01 | |
| US201462058629P | 2014-10-01 | 2014-10-01 | |
| US201462088459P | 2014-12-05 | 2014-12-05 | |
| NZ72427715 | 2015-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ764110A true NZ764110A (en) | 2024-02-23 |
Family
ID=90670430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764110A NZ764110A (en) | 2014-05-01 | 2015-05-01 | Compositions and methods for modulating pkk expression |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ764110A (en) |
-
2015
- 2015-05-01 NZ NZ764110A patent/NZ764110A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011749A (en) | Compositions and methods for modulating pkk expression. | |
| AU2019268063A1 (en) | Compositions for modulating sod-1 expression | |
| PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
| EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
| PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| NZ755605A (en) | Compositions for modulating tau expression | |
| PH12017500601A1 (en) | Anti-tnf compounds | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| GB2541571A (en) | Pharmaceutical compositions | |
| BR112017003111A2 (en) | compositions and methods for the treatment of neurological disorders | |
| EP3978610A3 (en) | Compositions for modulating ataxin 2 expression | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| EP3715457A3 (en) | Modulation of prekallikrein (pkk) expression | |
| MX2022007436A (en) | Autotaxin inhibitors and uses thereof. | |
| PH12017501990A1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| MX2017014456A (en) | Therapeutic uses of l-4-chlorokynurenine. | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| NZ764110A (en) | Compositions and methods for modulating pkk expression | |
| JO3621B1 (en) | Compounds And Compositions As Toll-Like Receptor 7 Agonists |